Skip to main content
. 2022 Mar 8;135(6):697–706. doi: 10.1097/CM9.0000000000002056

Figure 1.

Figure 1

Flow chart of recurrence risk prediction model construction. (a) Cases with effective recurrence and metastasis were allocated to the training set and the test set at a ratio of 2:1. (b) The test set included effective cases with recurrence and metastasis and effective cases without recurrence and metastasis at a ratio of 1:1; the remaining effective cases without recurrence were assigned to the training set.